Login to Your Account



Clinic Roundup


Friday, October 5, 2012

• Circassia Ltd., of Oxford, UK, started a pivotal, large-scale Phase III study of its ToleroMune cat allergy treatment for rhinoconjunctivitis. The study will test safety and efficacy of the ToleroMune treatment in approximately 1,200 subjects from the U.S., Canada and Europe.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription